{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:12:39Z","timestamp":1778047959502,"version":"3.51.4"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AMAG Pharmaceuticals, Waltham, Massachusetts"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0171098","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T18:42:34Z","timestamp":1485801754000},"page":"e0171098","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study"],"prefix":"10.1371","volume":"12","author":[{"given":"James B.","family":"Wetmore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Weinhandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,1,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","article-title":"Iron deficiency anaemia","volume":"387","author":"A Lopez","year":"2016","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/ajkd.2001.27699","article-title":"Anemia: an early complication of chronic renal insufficiency","volume":"38","author":"WH Kazmi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00041552-200205000-00011","article-title":"Epidemiology of anemia associated with chronic renal insufficiency","volume":"11","author":"CY Hsu","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988\u20131994)","volume":"162","author":"BC Astor","year":"2002","journal-title":"Arch Intern Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2215\/CJN.01670408","article-title":"Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988\u20132004","volume":"4","author":"S Fishbane","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 3","key":"ref6","first-page":"S1","article-title":"KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"ref7","first-page":"288","article-title":"KDIGO Clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","article-title":"A systematic analysis of global anemia burden from 1990 to 2010","volume":"123","author":"NJ Kassebaum","year":"2014","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jama.1997.03540360041028","article-title":"Prevalence of iron deficiency in the United States","volume":"277","author":"AC Looker","year":"1997","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3945\/ajcn.2008.27151","article-title":"Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003\u20132006","volume":"89","author":"ME Cogswell","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","article-title":"Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993\u20132005","volume":"12","author":"E McLean","year":"2009","journal-title":"Public Health Nutr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0272-6386(95)90105-1","article-title":"Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin","volume":"25","author":"RL Wingard","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2326-11-4","article-title":"Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data","volume":"11","author":"RA Moore","year":"2011","journal-title":"BMC Blood Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1185\/03007995.2012.761599","article-title":"Tolerability of different oral iron supplements: a systematic review","volume":"29","author":"MJ Cancelo-Hidalgo","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1440-1754.1999.t01-1-00351.x","article-title":"An iron treatment trial in an aboriginal community: improving non-adherence","volume":"35","author":"SG Kruske","year":"1999","journal-title":"J Paediatr Child Health"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0272-6386(96)90463-1","article-title":"Safety of intravenous iron dextran in hemodialysis patients","volume":"28","author":"S Fishbane","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0272-6386(99)70183-6","article-title":"Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans","volume":"33","author":"G Faich","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0272-6386(01)80123-2","article-title":"Suspected iron dextran-related adverse drug events in hemodialysis patients","volume":"37","author":"R Fletes","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1523-1755.2003.00703.x","article-title":"Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients","volume":"63","author":"DW Coyne","year":"2003","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ndt\/gfi253","article-title":"Update on adverse drug events associated with parenteral iron","volume":"21","author":"GM Chertow","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/ndt\/gfh185","article-title":"On the relative safety of parenteral iron formulations","volume":"19","author":"GM Chertow","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/08860220701278208","article-title":"Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?","volume":"29","author":"T Sav","year":"2007","journal-title":"Ren Fail"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/sj.ki.5002779","article-title":"Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease","volume":"73","author":"M Auerbach","year":"2008","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1002\/ajh.23322","article-title":"Comparative rates of adverse events with different formulations of intravenous iron","volume":"87","author":"MM Okam","year":"2012","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.05320513","article-title":"A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD","volume":"9","author":"IC Macdougall","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"JE Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.iac.2014.04.013","article-title":"Hypersensitivity from intravenous iron products","volume":"34","author":"AJ Bircher","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1778-428X.2007.00042.x","article-title":"Adverse events associated with intravenous iron infusion low-molecular-weight iron dextran and iron sucrose): a systematic review","volume":"9","author":"J Critchley","year":"2007","journal-title":"Transfus Altern Transfus Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"M Auerbach","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000046199","article-title":"Adverse events in chronic hemodialysis patients receiving intravenous iron dextran\u2014a comparison of two products","volume":"20","author":"JT McCarthy","year":"2000","journal-title":"Am J Nephrol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"BS Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.02840608","article-title":"Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients","volume":"4","author":"R Provenzano","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref33","unstructured":"Food &amp; Drug Administration. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm440138.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm440138.htm<\/ext-link>. Accessed: August 16, 2016"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2015.15572","article-title":"Comparative risk of anaphylactic reactions associated with intravenous iron products","volume":"314","author":"C Wang","year":"2015","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/ndt\/gfv305","article-title":"Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients","volume":"30","author":"M Airy","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/j.ajkd.2013.02.360","article-title":"Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement report","volume":"62","author":"ED Weinhandl","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2015.3713","article-title":"New anthrax treatment approved","volume":"313","author":"R Rubin","year":"2015","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2146\/ajhp110262","article-title":"Comparison of rates of reported adverse events associated with i.v. iron products in the United States","volume":"69","author":"GR Bailie","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21794","article-title":"Use of parenteral iron products and serious anaphylactic-type reactions","volume":"85","author":"DK Wysowski","year":"2010","journal-title":"Am J Hematol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2146\/ajhp120138","article-title":"Caution in making inferences from FDA&apos;s Adverse Event Reporting System","volume":"69","author":"M Auerbach","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ajh.23712","article-title":"A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy","volume":"89","author":"D Hetzel","year":"2014","journal-title":"Am J Hematol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ajh.23534","article-title":"Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min","volume":"88","author":"M Auerbach","year":"2013","journal-title":"Am J Hematol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clinthera.2013.09.028","article-title":"Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period","volume":"36","author":"B Schiller","year":"2014","journal-title":"Clin Ther"},{"key":"ref44","first-page":"1","article-title":"Epidemiology of adverse reactions to nonsteroidal antinflammatory drugs","volume":"6","author":"JCP Weber","year":"1984","journal-title":"Adv Inflamm Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration&apos;s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"KB Hoffman","year":"2014","journal-title":"Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0171098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T03:17:41Z","timestamp":1568776661000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0171098"}},"subtitle":[],"editor":[{"given":"Abelardo I","family":"Aguilera","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0171098","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,30]]}}}